iTeos Therapeutics (ITOS) to Wind Down Operations

iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value.

Following a thorough assessment of the Company’s development pipeline, business prospects, and financial position, the Company’s Board of Directors intends to wind down clinical and operational activities and focus on leveraging the Company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the Company’s intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Bimini Capital Management (BMNM) Tops Q2 EPS by 4c
• Artiva Biotherapeutics, Inc. (ARTV) Misses Q2 EPS by 63c